Demethylation of theMIR145promoter suppresses migration and invasion in breast cancer

// Shui-Yi Liu 1, 2, * , Xiao-Yi Li 1, * , Wei-Qun Chen 1, 2, 3, * , Hui Hu 1 , Bo Luo 6 , Yu-Xiang Shi 6 , Tang-Wei Wu 1 , Yong Li 1, 7 , Qing-Zhi Kong 2, 3, 4, 5 , Hong-Da Lu 2, 3, 4, 5 and Zhong-Xin Lu 1, 2, 3, 4 1 Department of Medical Laboratory, Central Hospital of Wuhan, Wuhan 430014, China 2 Cancer Research Institute of Wuhan, Wuhan 430014, China 3 Department of Central Laboratory, Central Hospital of Wuhan, Wuhan 430014, China 4 Key Laboratory for Molecular Diagnosis of Hubei Province, Central Hospital of Wuhan, Wuhan 430014, China 5 Department of Oncology, Central Hospital of Wuhan, Wuhan 430014, China 6 Department of Pathology, Central Hospital of Wuhan, Wuhan 430014, China 7 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA * These authors have contributed equally to this work Correspondence to: Zhong-Xin Lu, email: lzx71@yahoo.com Hong-Da Lu, email: phlonda@163.com Keywords: miR-145, methylation, breast cancer, ANGPT2, migration and invasion Received: November 04, 2016 Accepted: May 12, 2017 Published: June 27, 2017 ABSTRACT miR-145 has been implicated in the progression of breast cancer. Here, we report that its expression is decreased in breast cancer specimens and cell lines and that this low level of expression is associated with DNA methylation of its gene, MIR145. Methylation of MIR145 has previously been correlated with cell migration and invasion, both in vivo and in vitro . We found that demethylation of MIR145 reactivates miR-145 and contributes to the anti-cancer properties of 5-aza-2′-deoxyazacytidine (5-AzaC). Therefore, miR-145 is a potentially valuable biomarker for breast cancer.